SCHEMBL8426408

SCHEMBL8426408

CC(=O)[C@@H]1CCCC(=O)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 9/20 0.36
HDAC11 Q96DB2 9/20 0.36
HDAC6 Q9UBN7 9/20 0.36
HDAC1 Q13547 8/20 0.36
HDAC2 Q92769 8/20 0.36
HDAC10 Q969S8 8/20 0.36
HDAC8 Q9BY41 8/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
ABL1 P00519 1/20 0.35
NCOR2 Q9Y618 2/20 0.34
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CRBN Q96SW2 1/20 0.32
TRHR P34981 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143334 1.00 HDAC3 (0.36) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL17995 0.94 HDAC3 (0.36) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL2132866 0.87
SCHEMBL3134625 0.87
SCHEMBL8920712 0.87
SCHEMBL15347243 0.83 HDAC3 (0.38) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL630497 0.81 CAD (0.43) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL3625069 0.81 CAD (0.43) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL2344195 0.81 CAD (0.43) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL14374129 0.79 GLI1 (0.44) HDAC3HDAC11HDAC6HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377872-B2 Non-structural protein-3 (NS-3) protease inhibitors; viricides ENANTA PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20080267916-A1 CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-10-30 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same AVPR1B, PRLHR, HRH4 HDAC3 612/4885HDAC11 568/4885HDAC6 678/4885
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same AVPR1B, HRH4, PRLHR HDAC3 448/4885HDAC11 570/4885HDAC6 606/4885
US-20080267916-A1 CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, CTSC, PREP HDAC3 425/4885HDAC11 945/4885HDAC6 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.